These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9316434)

  • 1. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects.
    Watts GF; Naoumova RP; Kelly JM; Riches FM; Croft KD; Thompson GR
    Am J Physiol; 1997 Sep; 273(3 Pt 1):E462-70. PubMed ID: 9316434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications.
    Watts GF; Cummings MH; Umpleby M; Quiney JR; Naoumova R; Thompson GR; Sönksen PH
    Eur J Clin Invest; 1995 Aug; 25(8):559-67. PubMed ID: 7589011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity.
    Riches FM; Watts GF; Naoumova RP; Kelly JM; Croft KD; Thompson GR
    Int J Obes Relat Metab Disord; 1998 May; 22(5):414-23. PubMed ID: 9622338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC; Watts GF; Barrett PH; Mori TA; Beilin LJ; Redgrave TG
    J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men.
    Riches FM; Watts GF; Hua J; Stewart GR; Naoumova RP; Barrett PH
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2854-61. PubMed ID: 10443691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
    Cuchel M; Schaefer EJ; Millar JS; Jones PJ; Dolnikowski GG; Vergani C; Lichtenstein AH
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct association between the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 and plasma mevalonic acid and lathosterol concentrations in man.
    Riches FM; Watts GF; Naoumova RP; Kelly JM; Croft KD; Thompson GR
    Atherosclerosis; 1997 Nov; 135(1):83-91. PubMed ID: 9395276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
    Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
    Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects.
    Watts GF; Naoumova R; Cummings MH; Umpleby AM; Slavin BM; Sönksen PH; Thompson GR
    Metabolism; 1995 Aug; 44(8):1052-7. PubMed ID: 7637647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
    Aguilar-Salinas CA; Barrett PH; Kelber J; Delmez J; Schonfeld G
    J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome.
    Watts GF; Chan DC; Barrett PH; O'Neill FH; Thompson GR
    Int J Obes Relat Metab Disord; 2003 Jul; 27(7):862-5. PubMed ID: 12821974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in cholesteryl ester storage disease.
    Cummings MH; Watts GF
    Clin Chem; 1995 Jan; 41(1):111-4. PubMed ID: 7813057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of hydroxymethylglutaryl coenzyme A reductase activity does not affect the secretion rate of apolipoproteins B and AI by CaCo-2 cells.
    Pau E; He Y; Lougheed M; Steinbrecher UP
    Biochem Cell Biol; 1995; 73(1-2):81-90. PubMed ID: 7662319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel inhibitor of oxidosqualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content.
    Telford DE; Lipson SM; Barrett PH; Sutherland BG; Edwards JY; Aebi JD; Dehmlow H; Morand OH; Huff MW
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2608-14. PubMed ID: 16210564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
    Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
    Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM.
    Cummings MH; Watts GF; Umpleby AM; Hennessy TR; Kelly JM; Jackson NC; Sönksen PH
    Diabetes; 1995 Sep; 44(9):1059-65. PubMed ID: 7657029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    J Lipid Res; 1999 Jul; 40(7):1317-27. PubMed ID: 10393217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.